Correction to: The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes: A New Zealand Evaluation (PharmacoEconomics, (2012), 30, 11, (1067-1084), 10.2165/11595080-000000000-00000);The cost effectiveness of genetic testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes: A New Zealand Evaluation

PharmacoEconomics

Volumn 30, Issue 11, 2012, Pages 1067-1084

  Panattoni, Laura ^a,f   Brown, Paul M ^a,b   Ao, Braden Te ^a   Webster, Mark ^a,c   Gladding, Patrick ^a,d,e  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d LERNER RESEARCH INSTITUTE   (United States)

^e Theranostics Laboratory   (United States)

^f PALO ALTO MEDICAL FOUNDATION RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALLELE; ARTICLE; ASIAN; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSIS RELATED GROUP; FEMALE; GENETIC SCREENING; GENETIC VARIABILITY; HEALTH CARE; HEART DEATH; HEART INFARCTION; HETEROZYGOSITY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PACIFIC ISLANDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS;

EID: 84867290544     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-020-00885-8     Document Type: Erratum

References (33)

1. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358 (9281): 527-33
2. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108 (14): 1682-7
3. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 338: 2001-15
4. Mahoney EM, Wang K, Arnold SV, et al. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel - thrombolysis in myocardial infarction TRI-TON-TIMI 38. Circulation 2010; 121: 71-9
5. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62
6. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119: 2553-60
7. US FDA. FDA drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug [online]. Available from URL: http://www.fda.gov/drugs/drugsafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm [Accessed 2010 Apr 5]
8. Lea RA, Roberts RL, Green MR, et al. Allele frequency differences of cytochrome P450 polymorphisms in a sample of New Zealand Maori. N Z Med J 2008; 121 (1272): 33-7
9. Robarge J, Fletcher R, Nguyen A, et al. Gene: CYP2C19 [online]. Available from URL: http://www.pharmgkb.org/search/annotatedGene/cyp2c19/haplotype. jsp#ImportantHaplotypeInformationforCYP2C19-2 [Accessed 2010 Jan 20]
10. New Zealand Ministry of Health. National Minimum Dataset: hospital events [online]. Available from URL: http://www.health.govt.nz/nz-health-statistics/ national-collections-and-surveys/collections/national-minimum-dataset- hospitalevents [Accessed 2012 Aug 4]
11. Riddell T, North D. Socioeconomic and ethnic inequalities in cardiovascular disease: technical report to medical and Allied Health Professionals [report no. 80]. Auckland: National Heart Foundation, 2003
12. Pharmaceutical Management Agency. New Zealand pharmaceutical schedule. Wellington: PHARMAC, 2006
13. New Zealand Health Information Service. New Zealand casemix framework for publicly funded hospitals including WIESNZ08 methodology and casemix purchase unit allocation for the 2008/09 financial year [online]. Available from URL: http://www.health.govt.nz/system/files/documents/pages/wiesnz08-methodology.doc [Accessed 2012 Aug 4]
14. Pharmaceutical Management Agency. Section H of the Pharmaceutical Schedule (hospital pharmaceuticals), effective 1 Dec 2009 [online]. Available from URL: http://www.pharmac.govt.nz/SchedulePublications [Accessed 2012 Aug 4]
15. Teao BJ, Brown PM, Feigin VL, et al. Are stroke units cost effective? Evidence from a New Zealand stroke incidence and population-based study. Int J Stroke. Epub 2011 Oct 20
16. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes study: initial catalog of health-state quality factors. Med Dec Making 1993; 13: 89-102
17. Lord SJ, Allen F, Atherton JJ, et al. A systematic review and economic analysis of drug-eluting coronary stent available in Australia. Med J Australia 2005; 183 (9): 464-71
18. Statistics New Zealand. Complete period life tables: 2005-2007 [online]. Available from URL: http://www.stats.govt.nz/methods-and-services/access-data/ tables/period-life-tables.aspx [Accessed 2010 Jan 10]
19. Karnon J, Holmes M, Williams R, et al. A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK. Int J Cardiol 2008; 140 (3): 315-22
20. US FDA. Effient label [online]. Available from URL: http://www. accessdata.fda.gov/drugsatfda-docs/label/2010/022307s002lbl.pdf [Accessed 2012 Aug 4]
21. Sorich MJ, Vitry A, Ward MD, et al. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J Thromb Haemost 2010; 8: 1678-84
22. Congressional Budget Office. Research on the comparative effectiveness of medical treatments. Washington, DC: Congressional Budget Office, 2007
23. Berger CJ, Joanne MM, Evans JC, et al. Prognosis after first myocardial infarction: comparison of Q-wave and non-Q-wave myocardial infarction in the Framingham Heart Study. JAMA 1992; 268 (12): 1545-51
24. Fox KAA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006; 333 (7578): 1091
25. *17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010 Feb 2; 121 (4): 512-8
26. Epstein RS, Moyer TP, Aubert RE, et al. Warfarin genotyping reduces hospitalization rates: results from the MM-WES (Medco-Mayo Warfarin Effectiveness Study). J Am Coll Cardiol 2010; 55: 2804-12
27. Ray T. Vanderbilt Medical Center initiates Plavix PGx testing for all cardiac catheterization patients. Pharmacogenomics Reporter 2010 Oct 6 [online]. Available from URL: http://www.genomeweb.com/dxpgx/vanderbilt-medical-center- initiates-plavix-pgx-testing-all-cardiac-catheterizati [Accessed 2011 Jan 15]
28. Holmes D, Dehmer G, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "Boxed Warning". J Am Coll Cardiol 2010; 56: 321-41
29. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
30. Steinhubl SR, Berger PB, Mann 3rd JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288 (19): 2411-20
31. Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362: 1374-82
32. Hsu HL, Woad KJ, Woodfield DG, et al. A high incidence of polymorphic CYP2C19 variants in archival blood samples from Papua New Guinea. Hum Genomics 2008; 3 (1): 17-23
33. Takakubo F, Kuwano A, Kondo I. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese. Pharmacogenetics 1996; 6 (3): 265-7